ArticleBritish journal of clinical pharmacology2018
Missed opportunities: unnecessary medicine use in patients with lung cancer at the end of life - an international cohort study.
Article in British journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Deprescribing for Comorbidities in Patients with Cancer - a Systematic Review.Current oncology reports · 2026Pooled it
- Deprescribing in palliative patients with cancer: a concise review of tools and guidelines.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Pooled it
- Clinician perspectives on antithrombotic therapy management in advanced cancer: a multinational qualitative study.Research and practice in thrombosis and haemostasis · 2026Article
- Anti-thrombotic therapy in patients with cancer at the end of life: A cohort study using population-linked routinely collected data.British journal of haematology · 2025Article
- "Starting to think that way from the start": approaching deprescribing decision-making for people accessing palliative care - a qualitative exploration of healthcare professionals views.BMC palliative care · 2024Article
- DEprescribing: Perceptions of PAtients living with advanced cancer. A multicentre, prospective mixed observational study protocol.PloS one · 2024Article
- The potential for deprescribing in a palliative oncology patient population: a cross-sectional study.European journal of hospital pharmacy : science and practice · 2023Article
- Statin discontinuation in persons with and without Alzheimer's disease.European journal of clinical pharmacology · 2022Article
- Deprescribing in Palliative Cancer Care.Life (Basel, Switzerland) · 2022Review
- Sex-Differences in Discontinuation of Statin Treatment in Cancer Patients the Year before Death.Pharmaceuticals (Basel, Switzerland) · 2021Article
- A systems approach to identifying the challenges of implementing deprescribing in older adults across different health-care settings and countries: a narrative review.Expert review of clinical pharmacology · 2020Review
- Missed opportunities: unnecessary medicine use in patients with lung cancer at the end of life - an international cohort study.British journal of clinical pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aims of the current study were: (i) to examine the prescribing of preventative medication in a cohort of people with advanced lung cancer on hospital admission and discharge across different healthcare systems; and (ii) to explore the factors that influence preventative medication prescribing at hospital discharge.
methodsA retrospective cohort study was conducted across two centres in the UK and the US. The prescribing of preventative medication was examined at hospital admission and discharge for patients who died of lung cancer. A zero-inflated negative binomial regression model was used to examine the association between preventative medications at discharge and patient- and hospital-based factors. The classes of preventative medication prescribed included were: vitamins and minerals, and antidiabetic, antihypertensive, antihyperlipidaemic and antiplatelet medications.
resultsIn the UK site (n = 125), the mean number of preventative medications prescribed was 1.9 [standard deviation (SD) 1.7) on admission, and 1.7 (SD 1.7) on discharge, and in the US site (n = 191) the mean was 2.6 (SD 2.2) on admission and 1.9 (SD 2.2) on discharge. The model found a significant association between the number of preventative drugs prescribed on admission and the number on discharge; it also found a significant association between the total number of drugs prescribed on discharge and the number of preventative medications on discharge. Other indicators related to patient and hospital factors were not significantly associated with the number of preventative medications supplied on discharge.
conclusionsThe use of preventative medication was common in lung cancer patients, despite undergoing discharge. Patient- and hospital-based factors did not influence the prescribing of preventative medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.